Plant ID: NPO29271
Plant Latin Name: Erycibe obtusifolia
Taxonomy Genus: Erycibe
Taxonomy Family: Convolvulaceae
NCBI TaxonomyDB:
1603722
Plant-of-the-World-Online:
267907-1
Vietnam; China
DRD1; | |
CA7; CA1; CA12; CA9; CA13; | |
GFER; HSD17B10; AKR1B1; ALOX15; ALDH1A1; AKR1B10; | |
CASP7; CASP1; | |
HIF1A; | |
XDH; | |
APP; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.710E-12 | 2.950E-08 | CA1, CA12, CA13, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.353E-10 | 2.433E-06 | CA1, CA12, CA13, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.605E-10 | 5.229E-06 | CA1, CA12, CA13, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.210E-08 | 4.813E-05 | CYP1A2, CYP2C19, CYP2D6 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.362E-07 | 2.472E-04 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.901E-07 | 2.847E-04 | AKR1B1, AKR1B10, APP, CYP1A2, CYP2C19, CYP2D6 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.696E-07 | 8.100E-04 | ALOX15, CYP1A2, CYP2C19, CYP2D6, XDH |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 9.135E-07 | 1.047E-03 | AKR1B1, AKR1B10, ALDH1A1, CYP1A2, CYP2C19, CYP2D6, DRD1 |
MF | GO:0005488; binding | GO:0048037; cofactor binding | 9.343E-06 | 7.825E-03 | ALDH1A1, CYP1A2, CYP2C19, CYP2D6, GFER, XDH |
MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 1.282E-05 | 9.971E-03 | AKR1B1, AKR1B10, HSD17B10, XDH |
CC | GO:0044464; cell part | GO:0005829; cytosol | 6.907E-05 | 3.418E-02 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, APP, CA1, CA13, CA7, CASP1, CASP7, GFER, HIF1A, LMNA, XDH |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.687E-12 | 2.437E-10 | CA12, CA1, CA7, CA9, CA13 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.182E-06 | 8.982E-05 | APP, CYP2D6, ALOX15, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.582E-06 | 8.982E-05 | CYP1A2, ALOX15, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.086E-05 | 2.169E-04 | AKR1B10, CYP1A2, ALOX15, ALDH1A1, AKR1B1, CYP2C19, HSD17B10, XDH |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.999E-05 | 4.333E-04 | CYP2D6, CYP1A2, CYP2C19 |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 6.928E-04 | 3.602E-03 | APP, CASP7, HSD17B10 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 6.474E-04 | 3.602E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 4.487E-04 | 3.322E-03 | AKR1B10, AKR1B1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.508E-03 | 7.128E-03 | CASP7, CASP1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00561 | Glycerolipid metabolism | 1.733E-03 | 7.510E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.912E-03 | 7.647E-03 | ALOX15, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 5.110E-04 | 3.322E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.099E-03 | 7.795E-03 | CYP1A2, ALDH1A1 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.048E-05 | 1.362E-04 | CYP1A2, XDH |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.638E-03 | 9.043E-03 | CYP2D6, CYP1A2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 2.782E-03 | 9.043E-03 | CASP7, CASP1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
NA: NA | Geographic retinal atrophy | NA | APP; |
C00-D49: Neoplasms | Glioma | C71 | APP; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | APP; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | APP; CA9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |